

The opinion in support of the decision being entered today was not written for publication and is not binding precedent of the Board.


UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Ex parte MARC ALIZON,
FRANCOIS BARRE SINOUSSE, PIERRE SONIGO,
PIERRE TIOLLAIS, JEAN-CLAUDE CHERMANN,
LUC MONTAGNIER, and SIMON WAIN-HOBSON

Appeal No. 2005-0256
Application No. 08/466,921

HEARD: April 19, 2005



Before WILLIAM F. SMITH, MILLS, and GRIMES, Administrative Patent Judges.

WILLIAM F. SMITH, Administrative Patent Judge.

DECISION ON APPEAL

This is an appeal under 35 U.S.C. § 134 from the final rejection of claims 62-73. Claims 39-52, 60, and 61 are pending and are free of rejection.¹ Claims 62-73 read as follows:

¹ An order remanding the application to the examiner to consider a number of issues was entered on June 27, 2002. At that time claims 39-52, 60, and 61 were free of rejection. The remand asked the examiner to review the patentability of those claims in light of recent precedent. Remand, pages 4-5. The remand also stated that a Supplemental Examiner's Answer was not authorized under the then-existing provisions of 37 CFR § 1.193(b)(1). Despite that admonition, the examiner entered a Supplemental Examiner's Answer on March 12, 2004. Appellants responded by way of a Supplemental Reply Brief on May 12, 2004.

While the Supplemental Examiner's Answer was not authorized, appellants have responded thereto and have not urged that they were prejudiced by the examiner's action. Given the length of time it took the examiner to respond to the previous remand and the lack of any apparent prejudice to appellants, we have taken the case up for decision having heard oral argument. We note that the examiner confirmed the patentability of claims 39-52, 60, and 61. Supp. Ex. Ans., pages 12-13.

62. A purified DNA fragment of HIV-1 consisting of a restriction fragment, wherein the fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

63. The fragment of claim 62, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

64. A cloned DNA fragment of HIV-1, wherein said fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

65. The fragment of claim 64, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

66. An isolated double-stranded DNA fragment of HIV-1, wherein a strand of said fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

67. The fragment of claim 66, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

68. An amplified copy of a DNA fragment of HIV-1, wherein said fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

69. The copy of claim 68, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

70. A vector comprising an HIV-1 DNA fragment, wherein said fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

71. The vector of claim 70, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

72. A host cell transformed with a vector comprising an HIV-1 DNA fragment, wherein said fragment hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1%SDS, at 37°C.

73. The host cell of claim 72, wherein the hybridizing genomic HIV-1 DNA is λ J19 DNA.

Claims 62-73 stand rejected under 35 U.S.C. § 112, first paragraph (written description). In addition, claims 68 and 69 stand rejected under 35 U.S.C. 112, second paragraph as being indefinite. We affirm the written description rejection and reverse the indefiniteness rejection.

Background

The present invention is directed to DNA fragments of human immunodeficiency virus type 1 (HIV-1) and vectors and host cells containing certain of the fragments. The technology described in the specification relates to “cloned DNA sequences hybridizable to genomic RNA and DNA of lymphadenopathy-associated virus (LAV), a process for their preparation and their uses.” Specification, page 1.² Specifically,

The present invention aims at providing new means which should not only also be useful for the detection of LAV or related viruses (hereafter more generally referred to as ‘LAV viruses’), but also have more versatility, particularly in detecting specific parts of the genomic DNA of said viruses whose expression products are not always detectable by immunological methods.

Id., page 2, lines 10-16. Appellants also state:

More particularly the invention relates to any fragment corresponding to the above ones, having substantially the same sites at substantially same distances from one another, all of those fragments having in common the capability of hybridizing with the LAV retroviral genomes. It is of course understood that fragments which would include some deletions or mutation which would not substantially alter their capability of also hybridizing with the LAV retroviral genomes are to be

² At some point in time, LAV was renamed HIV-1. While the specification of this application refers to LAV, the claims on appeal refer to HIV-1. Consistent with the usage of HIV-1 in the claims under review, we shall refer to the virus as HIV-1.

considered as forming obvious equivalents of the DNA fragments more specifically referred to hereabove.

Id., page 5, first full paragraph.

Discussion

A. Written Description.

A review of the original disclosure reveals that the subject matter set forth in the claims on appeal was not explicitly described at the time this application was filed. This does not mean that those claims lack written description. Eiselstein v. Frank, 52 F.3d 1035, 1038, 34 USPQ2d 1467, 1470 (Fed. Cir. 1995) (“[T]he prior application need not describe the claimed subject matter in exactly the same terms as used in the claims . . .”). However, “[t]he applicant must . . . convey to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991) (emphasis in original). Thus, the analysis becomes whether the as filed application conveys to those skilled in the art that appellants were in possession of the DNA fragments set forth in claims 62-73.

Each claim on appeal requires that the claimed DNA fragment “hybridizes to the genomic DNA of HIV-1 under hybridization conditions of 20% formamide, 8X SSC, at 37°C, with washes in 2X SSC, 0.1% SDS, at 37°C.” However, these hybridization and washing conditions are described in the original disclosure of this application as those that were used to compare “LAV with a number of human endogenous viral genomes ...

under non stringent conditions....” Specification, page 12, lines 4-6. Nowhere does the original disclosure of this application describe DNA fragments hybridizing under the claimed conditions as part of appellants’ invention. Rather, it appears that appellants have cobbled together disparate portions of the original disclosure in an attempt to claim DNA fragments in a manner not described when the application was filed. As stated in Rengo Co. v. Molins Mach. Co., 657 F.2d 535, 551, 211 USPQ 303, 321 (3d Cir. 1981) “[a]dequate description of the invention guards against the inventor’s overreaching by insisting that he recount his invention in such detail that his future claims can be determined to be encompassed within his original creation.”

We also note that since the time the original Appeal Brief and Reply Brief were filed in this case, June 21, 2000 and November 9, 2000, respectively, our appellate reviewing court has addressed written description issues involving DNA. As recognized by appellants in the Supplemental Reply Brief of May 12, 2004, the most relevant precedent is Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316, 63 USPQ2d 1609 (Fed. Cir. 2002) (Enzo II). We have considered appellants’ arguments in regard to Enzo II vis-à-vis claims 62-73 of this application but do not find those arguments persuasive.

In considering Enzo II, we note that present claims 62-73 are directed to two separate embodiments. First, there are claims that only require a purified DNA fragment of HIV-1 that consists of a restriction fragment that hybridizes to the “genomic DNA of HIV-1” under the specified hybridization and wash conditions. See, e.g., claim 62. Then there are claims directed to a narrower embodiment wherein the hybridizing

genomic HIV-DNA is λ J19 DNA. See, e.g., claim 63. Appellants argue that the recitation in the claims that the required DNA fragment is a “HIV-1” DNA fragment imposes a structural limitation, as do the claim requirements in regard to hybridization and wash conditions and λ J19 DNA. We agree with appellants that the claims do set forth structural requirements for the claimed DNA fragments as argued. However, we do not find that those structural requirements serve to define a genus of DNA fragments that enjoys proper written descriptive support in the original disclosure of this application. This conclusion includes both the broad and narrow embodiments set forth in the claims on appeal.

The “Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 ‘Written Description’ Requirement,” 66 Fed. Reg. 1099 (Jan. 5, 2001) (“Guidelines”) were discussed in Enzo II. The court noted that the PTO “has determined that [genus claims to nucleic acids based on their hybridization properties] may be adequately described if they hybridize under highly stringent conditions to known sequences because such conditions dictate that all species within the genus will be structurally similar. See [Guidelines], Example 9, at 35-37.” Enzo II, 296 at 1327, 63 USPQ2d at 1615. Appellants rely upon this aspect of Enzo II in the Supplemental Reply Brief. See, e.g., pages 6-7. However, in making these arguments, appellants assiduously avoid recognizing that the hybridization conditions discussed by the court and which appear in Example 9 of the Guidelines are “highly stringent” while the hybridization and washing conditions required by each of claims 62-73 are stated by appellants at page 12 of the specification to be “non stringent.” Furthermore, the stated hybridization and

washing conditions are in the specification in order to distinguish the DNA fragments of the present invention from other viral genomes, not as part of defining appellants' invention. Thus, neither Enzo II nor the Guidelines provide appellants any support in their quest to receive patent protection for the genus of DNA set forth in any of claims 62-73.

The written description rejection is affirmed.

B. Indefiniteness.

The examiner rejects claims 68 and 69 under 35 U.S.C. § 112, second paragraph, as being indefinite since

the reference to 'amplified' copies of HIV-1 DNA fragments is vague and indefinite. The disclosure fails to provide an adequate definition of this phrase. This phrase is confusing since the precise nature of the amplification is not clearly set forth. For instance, it is not readily manifest if the claims are directed toward the amplification and plaque purification of a lambda phage clone containing an HIV-1 insert, PCR amplified HIV-1 fragments (which are clearly not supported by the disclosure), or some other form of amplified DNA. Moreover, Appellants have failed to provide any literature at the time of filing providing a suitable definition. Accordingly, the skilled artisan would not be able to ascertain the precise metes and bounds of the claimed invention.

Supplemental Answer, page 4. From this it appears that the examiner is concerned that the phrase "amplified copy" is confusing unless the nature of the amplification is set forth in the claims. However, the examiner has not established by way of evidence that the manner of amplification necessarily affects the structure of the DNA product or that a person skilled in the art would have difficulty understanding what is meant by "amplified."


The issue raised by the examiner appears to be more directed to the written description requirement of the statute instead of claim definiteness since the examiner relies on the fact that appellants have only described in the original disclosure of this application a single type of amplified DNA, yet now present claims directed to amplified DNA fragments without reference to how the amplification took place. Whether appellants are entitled to claim such a broad genus in this case is an issue more properly raised under the written description requirement.

The examiner's indefiniteness rejection is reversed.

The decision of the examiner is affirmed.

No time period for taking any subsequent action in connection with this appeal may be extended under 37 CFR § 1.136(a).

AFFIRMED


William F. Smith

Administrative Patent Judge


Demetra Mills

Administrative Patent Judge


Eric Grimes

Administrative Patent Judge

)
)
)
)
) BOARD OF PATENT
)
) APPEALS AND
)
) INTERFERENCES
)
)

Appeal No. 2005-0256
Application No. 08/466,921

Kenneth J. Meyers
Finnegan, Henderson, Farabow,
Garrett & Dunner
901 New York Avenue, NW
Washington, DC 20001-4413

dem